Metformin may have dual effect in breast cancer

May 9, 2012
Metformin may have dual effect in breast cancer

(HealthDay) -- For women without diabetes and with operable breast cancer, administration of metformin prior to surgery does not significantly affect the proliferative marker Ki-67 overall, but drug effects are observed according to homeostasis model assessment (HOMA), particularly in luminal B tumors, according to a study published online May 7 in the Journal of Clinical Oncology.

Bernardo Bonanni, M.D., of the European Institute of Oncology in Milan, and colleagues conducted a randomized trial involving 200 women without diabetes and with operable early-stage who were given either metformin or placebo. The authors sought to investigate the effect of metformin given before surgery on Ki-67.

The researchers found that metformin did not significantly affect Ki-67 compared with placebo. However, in women with HOMA index of greater than 2.8, Ki-67 decreased nonsignificantly, by 10.5 percent, compared with a nonsignificant increase of 11.1 percent in those with HOMA index of 2.8 or lower. In luminal B tumors, metformin had a different effect according to HOMA index (Pinteraction = 0.05). Drug effect modification was demonstrated, with similar trends seen for , waist/hip girth-ratio, , and C-reactive protein.

"In conclusion, our results suggest a heterogeneous effect of metformin on breast cancer proliferation depending on insulin resistance and other factors reflecting altered energy balance, with a trend to a decreased proliferation in women with elevated HOMA index and an opposite trend in women with normal insulin sensitivity," the authors write.

The metformin and placebo used in the study were donated by Laboratori Guidotti in Pisa, Italy.

Explore further: Researchers test a drug-exercise program designed to prevent type 2 diabetes

More information: Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Related Stories

Metformin appeared to slow prostate cancer growth

April 1, 2012

The use of metformin in men with prostate cancer before prostatectomy helped to reduce certain metabolic parameters and slow the growth rate of the cancer, according to the results of a phase II study.

Recommended for you

Study examines evolution of cancer

February 8, 2016

A novel Yale study answers age-old questions about how cancers spread by applying tools from evolutionary biology. The new insights will help scientists better understand the genetic origins of tumor metastases, and lead ...

The growing menace of HPV‑related throat and mouth cancers

February 2, 2016

There's a new cancer epidemic on the rise. It's an aggressive throat and mouth cancer caused by the human papillomavirus (HPV)—the same sexually transmitted virus that leads to cervical cancer—but it's affecting mostly ...

How gut inflammation sparks colon cancer

February 4, 2016

Chronic inflammation in the gut increases the risk of colon cancer by as much as 500 percent, and now Duke University researchers think they know why.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.